A Retrospective Study of COVID-19 Treatments
A Retrospective Study to Analyze Efficacy of COVID-19 Treatments
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ginger Aurella
- Phone Number: 805-339-0549
- Email: ginger@progenabiome.com
Study Locations
-
-
California
-
Ventura, California, United States, 93003
- Ginger Aurella
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
- Male or female of 18 years of age or older
- Diagnosis of COVID-19 infection by RT- PCR
- Recovery from COVID-19
Exclusion Criteria:
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
COVID-19 Patients
Subjects who have recovered from COVID-19
|
There is no intervention in this study
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survey Response
Time Frame: One hour
|
Answers given by subjects on their recovery from COVID-19
|
One hour
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Sabine Hazan, MD, ProgenaBiome
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Infant, Newborn, Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Lung Injury
- Infant, Premature, Diseases
- COVID-19
- Infections
- Communicable Diseases
- Respiratory Tract Infections
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Bronchitis
- Respiratory Tract Diseases
Other Study ID Numbers
Other Study ID Numbers
- PRG-051
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.